Abstract:Dimethylarginine dimethylaminohydrolase-1 (DDAH1) modulates endothelial nitric oxide (NO) production by degrading asymmetric methylarginines that act as endogenous NO synthase (NOS) inhibitors. Since we recently found DDAH1 strongly expressed in vascular endothelial cells, this study examined effects of DDAH1 on endothelial function. Here, by using selective gene silencing of DDAH1 with small interfering RNA (siRNA) and overexpression of DDAH1 in HUVEC, we demonstrate that DDAH1 acts to promote endothelial cell proliferation, migration and tube formation both by the traditional role of degrading asymmetric methylarginines and a novel molecular pathway of increasing Akt activity. Specifically, overexpression of DDAH1 Abstracts From Scientific Sessions 2009 S1073 dose-dependently increased p-Akt Ser473 , Akt activity and p-eNOS Ser1177 , while selective gene silencing of DDAH1 with siRNA decreased endothelial p-Akt Ser473 and p-eNOS Ser1177 . Importantly, incubation of HUVEC with the NOS inhibitors L-NAME or ADMA, the soluble guanylyl cyclase inhibitor ODQ, or the membrane permeable cGMP analog 8-pCPT-cGMP had no effect on p-Akt Ser473 , indicating that the increase of p-Akt Ser473 produced by DDAH1 was NO and cGMP independent. Overexpression of constitutively active Akt rescued HUVEC from DDAH1 knockdown, while the increases of HUVEC tube formation, proliferation and migration after DDAH1 overexpression were abolished by the Akt inhibitor ly294002. Moreover, using endothelial specific DDAH1 gene deficient mice generated in our laboratory, we demonstrated that endothelial spouting from cultured aortic rings and in vivo vascular endothelial repair after wire injury were impaired compared to wild type mice. DDAH1 KO also attenuated vascular p-Akt Ser473 but not total Akt. Together, the data demonstrate that DDAH1 plays an important role in vascular endothelial cell growth and injury repair by regulating both NO production and Akt activity. This research has received full or partial funding support from the American Heart Association, National Center.

Repetitive Ischemia Increases Myocardial Dimethylarginine Dimethylaminohydrolase 1 Expression

Cardiomyocyte Dimethylarginine Dimethylaminohydrolase1 Attenuates Left-Ventricular Remodeling after Acute Myocardial Infarction: Involvement in Oxidative Stress and Apoptosis.

Cardiomyocyte Dimethylarginine Dimethylaminohydrolase-1 (DDAH1) Plays an Important Role in Attenuating Ventricular Hypertrophy and Dysfunction

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism

DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage

Dimethylarginine Dimethylaminohydrolase 1 Modulates Endothelial Cell Growth Through Nitric Oxide and Akt

Dimethylarginine Dimethylaminohydrolase-1 is the Critical Enzyme for Degrading the Cardiovascular Risk Factor Asymmetrical Dimethylarginine.

DDAH1/ADMA Regulates Adiponectin Resistance in Cerebral Ischemia via the ROS/FOXO1/APR1 Pathway

Effect of Asymmetric Dimethylarginine (ADMA) on Heart Failure Development

Abstract 5223: Dimethylarginine Dimethylaminohydrolase 1modulates Endothelial Cell Growth and Injury Repair Through No and Akt

Dimethylarginine Dimethylaminohydrolase 1 Deficiency Aggravates Monocrotaline-Induced Pulmonary Oxidative Stress, Pulmonary Arterial Hypertension and Right Heart Failure in Rats.

Ddah1 Deficiency Attenuates Endothelial Cell Cycle Progression and Angiogenesis

Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats

Changes in ADMA/DDAH pathway after hepatic ischemia/reperfusion injury in rats: the role of bile

Abstract 19689: Kdm3a Protects Myocardium from Ischemia/reperfusion Injury Through Targeting Akt-dependent Signaling Pathways

Vascular Endothelial-Specific Dimethylarginine Dimethylaminohydrolase-1–Deficient Mice Reveal That Vascular Endothelium Plays an Important Role in Removing Asymmetric Dimethylarginine

Relations Between Plasma Asymmetric Dimethylarginine (adma) and Risk Factors for Coronary Disease

Asymmetric Dimethylarginine Enables Depolarizing Spikes and Vasospasm in Mesenteric and Coronary Resistance Arteries

Asymmetric Dimethylarginine: A Novel Risk Factor for Cardiovascular Disease

Abstract 196: DDAH1 Knockout Exacerbates Hypoxia-induced Pulmonary Arterial Hypertension in Mice

Nitric Oxide Regulation of Myocardial O2 Consumption and HEP Metabolism.